急性冠状动脉综合征患者早期辛伐他汀干预对血脂和高敏C反应蛋白的影响

目的观察急性冠状动脉综合征(ACS)患者早期辛伐他汀治疗对血清高敏C反应蛋白(hs-CRP)和血脂水平的影响,探讨他汀类药物在ACS早期干预中的作用.方法选择住院的ACS患者80例,采用随机、单盲、对照方法将ACS患者分为对照组(n=38,每日口服安慰剂)和辛伐他汀治疗组(n=42, 辛伐他汀20 mg/d,发病48 h内开始服用),两组其他治疗相同;观察4周,于治疗前后分别检测患者血清hs-CRP及血脂的浓度.hs-CRP浓度采用酶联免疫吸附法测定,血脂采用酶法.结果治疗4周后,辛伐他汀组与对照组相比,患者血清hs-CRP和总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白胆固醇(LDL-C)浓度显著降低(P均<0.01),而对照组治疗前后差异无显著性(均为P>0.05).结论 ACS患者早期辛伐他汀治疗可明显改善血脂,降低hs-CRP水平.辛伐他汀具有减少炎症反应和稳定斑块的作用.

Therapeutic effect of simvastatin on serum lipids and high sensitive C-reactive protein in patients with acute coronary syndrome at the early stage

Objective to observe the effect of simvastatin on serum lipids and high sensitive C-reactive protein(hs-CRP) at the early stage in patients with acute coronary syndrome(ACS).Methods 80 hospitalized patients with ACS were selected and were randomly divided into control group(with placebo for 4 weeks,n=38) and simvastatin group(with simvastatin 20mg per day,n=42).Simvastatin and placebo were used within 48 hours from onset,and there were no other different therapeutic methods between two groups.The concentrations of serum lipids and hs-CRP were detected before and after 4 weeks treatment by ELISA and enzymatic cholesterol assay.Results In simvastatin group,levels of serum total cholesterol(TC),triglycerides(TG),lower density lipid cholesterol(LDL-C) and hs-CRP decreased significantly compared with those before treatment(P<0.01),but there was no significant change in control group(P>0.05),Conclusion Simvastatin can lower levels of serum lipids and hs-CRP in patients with acute coronary syndrome at the early stage,therefore simvastatin has anti-inflammatory therapeutic effect and may stabilize atherosclerotic plaques.